Does Mannose-Binding Lectin Plasma Level Predict the Incidence of Cytomegalovirus Disease in Solid-Organ Transplant Recipients?
CHUV, Lausanne
, Basel
, Zuerich
, Bern
, Geneva
, St Gallen, Switzerland
Meeting: 2013 American Transplant Congress
Abstract number: A585
Background: Mannose-binding lectin (MBL) is the initial component of the third complement activation pathway. Genetically-determined deficiency which is very prevalent has been implicated in the host defenses against bacteria and fungi among immunodeficient patients. Conflicting results have been published regarding its role in CMV susceptibility. We assessed the relationship between MBL genotype and phenotype and any relationship with the occurrence of CMV disease in a nationwide prospective cohort of SOT recipients in Switzerland.
Methods: Patients participating in the Swiss Transplant Cohort Study (STCS) and transplanted from May 2008 until March 2011 were included. MBL genotypes were determined using a custom-made Illumina Golden Gate Genotyping assay on Beadxpress® and SNP specific PCR respectively for 6 polymorphisms rs11003125, rs1800450, rs1800451, rs5030737, rs7096206 and rs709589. MBL plasma level was measured using BioPorto’s MBL Oligomer Kit 029 based on Mab HYB 131-0. The effect of affinity-purified hMBL was also tested on the infection of human embryonic lung fibroblasts and ARPE-19 cells by CMV.
Results: 1139 patients were included, had a MBL blood level determined and were genotyped. Genotype tightly predicted MBL blood level. Across the different serostatus risk pattern, patients with and without CMV disease did not differ in MBL blood level. When MBL blood level was used as a diagnostic test to predict CMV disease, a receiver operating curve analysis did not reveal any cut off value associated with occurrence of CMV disease either in the whole population (Figure left panel) or in CMV high risk recipients (right panel).
In vitro, hMBL did not inhibit CMV replication.
Conclusions: MBL deficiency was not associated with CMV disease in SOT recipients, nor did MBL inhibit CMV infection in vitro.
To cite this abstract in AMA style:
Pyndiah N, Kralidis G, Wójtowicz A, Bibert S, Manuel O, Mueller N, Hirsch H, Garzoni C, Delden Cvan, Berger C, Boggian K, Cusini A, Koller M, Weisser M, Pascual M, Bochud P, Meylan P, STCS The. Does Mannose-Binding Lectin Plasma Level Predict the Incidence of Cytomegalovirus Disease in Solid-Organ Transplant Recipients? [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/does-mannose-binding-lectin-plasma-level-predict-the-incidence-of-cytomegalovirus-disease-in-solid-organ-transplant-recipients/. Accessed May 14, 2025.« Back to 2013 American Transplant Congress